Natixis’s Lunai Bioworks LNAI Stock Holding History

Natixis’s Portfolio LNAI Stock Details LNAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,250	Closed	-$56.7K	–	1120
2023 Q2	$56.7K	Buy	1,250 +503	+67%	+$38.6K	﹤0.01%	837
2023 Q1	$54.7K	Buy	+747	New	+$65.7K	﹤0.01%	822

Other funds holding LNAI

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Natixis's LNAI Position: Q3 2023 in Review

Natixis sold out of Lunai Bioworks (LNAI) in Q3 2023, closing a stake of 1,250 shares — an estimated $56.7K sold.

Natixis first reported a position in LNAI in Q1 2023 and held it in 2 quarters. The position peaked at $56.7K in Q2 2023. 21 funds tracked by Wall St. Rank hold LNAI as of Q3 2023.

Natixis reported no remaining Lunai Bioworks position as of Q3 2023 after selling out during the quarter.
Natixis sold 1,250 Lunai Bioworks shares in Q3 2023, an estimated $56.7K.
Natixis first reported a position in Lunai Bioworks in Q1 2023 and held it in 2 quarters.
Natixis's Lunai Bioworks position peaked at $56.7K in Q2 2023.
21 funds tracked by Wall St. Rank held Lunai Bioworks as of Q3 2023.

Based on Natixis's 13F filing for Q3 2023, filed 14 Nov 2023.